Positive Opinion from the EU for Bevacizumab as Cervical Cancer Treatment

Positive Opinion from the EU for Bevacizumab as Cervical Cancer Treatment


Known as the blockbuster brand name anticancer therapy Avastin, Bevacizumab recently captured a positive opinion from the EU for its success in treating cervical cancer. On March 2, 2015 Roche Pharmaceuticals announced that the European Union’s (EU) Committee for Medicinal Products for Human Use expressed a positive opinion of Bevacizumab when used alongside standard chemotherapy for the treatment of cervical cancer. Studies of Bevacizumab, used in combination with either Paclitaxel and Cisplatin or Paclitaxel and Topotecan, in patients who were unable to receive platinum therapy, proved to be effectual for treating adult females with metastatic carcinoma of the cervix. With an estimated 33,000 new cases of cervical cancer predicted to be diagnosed in the EU in 2015, as well as one third of these patients not surviving this virulent disease, an anticipated approval of Bevacizumab as a therapy for cervical cancer is hopeful. The FDA already approved Bevacizumab in the United States for the treatment of recurrent and metastatic cervical cancer in August 2014. Bevacizumab is currently approved in the EU to treat advanced stages of breast cancer, non-small cell lung cancer, colorectal cancer, ovarian cancer and kidney cancer. The U.S. has approved the additional indications of cervical cancer and progressive glioblastoma following prior therapy for Bevacizumab.

As an effective anticancer medication that interferes with both the spread and growth of cancer cells Bevacizumab is typically given as part of a combination of treatments for cancer patients. Bevacizumab is dispensed intravenously about once every two weeks. While adverse effects can occur from Bevacizumab, such as excess bleeding and difficulty with wound healing, many patients experience tolerable side effects. Reported negative effects from Bevacizumab include body aches, bleeding gums, diarrhea, dizziness and tingling in the limbs.

Studies leading to the FDA approval of Bevacizumab in 2014 and the positive opinion from the EU in March of 2015 offered encouraging data for treating patients with cervical cancer. Initial survey results from studies with Bevacizumab were presented in 2013 at the American Society of Clinical Oncology annual meeting, which showed that patients with metastatic cervical cancer who were administered Bevacizumab lived an average of 3.7 months longer than their counterparts who did not receive this formidable drug. The aforementioned clinical trial, coined GOG240, was sponsored by the National Cancer Institute. The median age of patients was 47 years old and the approximate dose of Bevacizumab was 15 milligrams per kilogram (mg/kg) of their body weight via an intravenous drip. Treatment continued for patients one day every three weeks and was dispensed along with other chemotherapeutic drugs. Progression-free survival was 8.2 months for those patients who were given Bevacizumab, as compared to 5.9 months of progression –free survival for patients who were not administered Bevacizumab. By blocking the blood supply that feeds the tumors Bevacizumab is efficacious for both binding and inhibiting vascular endothelial growth factor. LGM Pharma can assist clients as a supplier/distributor of the API Bevacizumab CAS# 216974-75-3 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service